Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: chuncharunee s. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242045 Clinical Trial.
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.
Niparuck P, Sorakhunpipitkul L, Atichartakarn V, Chuncharunee S, Ungkanont A, Aungchaisuksiri P, Puavilai T, Jootar S. Niparuck P, et al. Among authors: chuncharunee s. J Hematol Oncol. 2010 Jan 5;3:1. doi: 10.1186/1756-8722-3-1. J Hematol Oncol. 2010. PMID: 20051128 Free PMC article.
Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability.
Intragumtornchai T, Bunworasate U, Siritanaratkul N, Khuhapinant A, Nawarawong W, Norasetthada L, Lekhakula A, Rujirojindakul P, Sirijerachai C, Chansung K, Suwanban T, Chuncharunee S, Niparuck P, Wongkhantee S, Mongkonsritragoon W, Numbenjapon T. Intragumtornchai T, et al. Among authors: chuncharunee s. Leuk Lymphoma. 2013 Jan;54(1):83-9. doi: 10.3109/10428194.2012.698739. Epub 2012 Jul 9. Leuk Lymphoma. 2013. PMID: 22646050
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B. Walewski J, et al. Among authors: chuncharunee s. Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30. Br J Haematol. 2018. PMID: 30168134 Free article. Clinical Trial.
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Chuncharunee S, Niparuck P, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasi N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T; Thai Lymphoma Study Group. Wudhikarn K, et al. Among authors: chuncharunee s. J Geriatr Oncol. 2020 Jan;11(1):62-68. doi: 10.1016/j.jgo.2019.03.016. Epub 2019 Mar 30. J Geriatr Oncol. 2020. PMID: 30940492
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Niparuck P, Chuncharunee S, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasri N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T; Thai Lymphoma Study Group. Wudhikarn K, et al. Among authors: chuncharunee s. Hematol Oncol. 2019 Dec;37(5):578-585. doi: 10.1002/hon.2687. Epub 2019 Nov 12. Hematol Oncol. 2019. PMID: 31702065
Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V. Niparuck P, et al. Among authors: chuncharunee s. J Med Assoc Thai. 2009 Sep;92(9):1143-9. J Med Assoc Thai. 2009. PMID: 19772172
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Taher AT, et al. Among authors: chuncharunee s. Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15. Blood. 2012. PMID: 22589472 Free article. Clinical Trial.
97 results